Filicium.com

Diseases &Amp; Conditions News

Amorfix reports new finding for vCJD blood screening assay and provides corporate updateFriday, September 12, 2008 @ 12:00PM Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, today reported that its EP-vCJD Blood Screening Assay can detect sporadic Creutzfeldt-Jakob Disease prions using brain material spiked into human plasma at the same sensitivity.

(AFX UK Focus) 2008-09-11 09:35 TFN NEWS BRIEFING: Mergers and acquisitions highlights to 09:20 BSTThursday, September 11, 2008 @ 4:56AM2008-09-11 09:16:55 INTERVIEW-Premier Farnell CEO eyes further Asia expansion

INDUSTRY & ECONOMYWednesday, September 10, 2008 @ 2:46PMMINING & QUARRYING: Mittal projects face 50% cost overruns Land acquisition, mining lease major hurdles.

Five New Studies at Major Medical Meeting Further Demonstrate Clinical Experience for JANUVIA(TM) (sitagliptin)Tuesday, September 9, 2008 @ 8:49AMNew data analyses presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed initial combination therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor, JANUVIA(TM) (sitagliptin), and metformin provided improvements in blood sugar levels (as measured by A1C(1)) over two years of treatment and was generally well tolerated. Also presented at the ...

Five New Studies at Major Medical Meeting Further Demonstrate Clinical Experience for JANUVIA(TM) (sitagliptin)Tuesday, September 9, 2008 @ 8:00AM WHITEHOUSE STATION, N.J.----New data analyses presented at the 44th Annual Meeting of the European Association for the Study of Diabetes showed initial combination therapy with the dipeptidyl peptidase-4 inhibitor, JANUVIA™ , and metformin provided improvements in blood sugar levels over two years of treatment and was generally well tolerated.